Cohen, W., Florida, R., Randasses, L. & Walsh, J. Industry and the academy: uneasy partners in the cause of technological advance. in R. Noll (Ed.), Challenges to Research Universities, 171–200, Washington, DC: The Brookings Institution (1998).
Jaffe, A. Real effects of academic research. Am. Econ. Rev. 79, 957–970 (1989).
Mansfield, E. Academic research and industrial innovation. Res. Policy 20, 1–12 (1991).
Roessner, D., Bond, J., Okubo, S. & Planting, M. The economic impact of licensed commercialized inventions originating in university research. Res. Policy 42, 23–34 (2013).
Pressman, L. et al. The licensing of DNA patents by US academic institutions: an empirical survey. Nat. Biotechnol. 24, 31–39 (2006).
Grimaldi, R., Kenney, M., Siegel, D.S. & Wright, M. 30 years after Bayh-Dole: reassessing academic entrepreneurship. Res. Policy 40, 1045–1057 (2011).
Macho-Stadler, I. & Perez-Castrillo, D. Incentives in university technology transfer. Int. J. Ind. Organ. 28, 362–367 (2009).
The Ewing Marion Kauffman Foundation. University Technology Transfer Through Entrepreneurship: Faculty and Students in Spinoffs. http://www.scribd.com/doc/102157856/University-Technology-Transfer-Through-Entrepreneurship-Faculty-and-Students-in-Spinoffs (2012).
Sampat, B.N. Academic patents and access to medicines in developing countries. Am. J. Public Health 99, 9–17 (2009).
Zycher, B., DiMasi, J.A. & Milne, C.-P. Private sector contributions to pharmaceutical science: thirty-five summary case histories. Am. J. Ther. 17, 101–120 (2010).
Kneller, R. The importance of new companies for drug discovery: origins of a decade of new drugs. Nat. Rev. Drug Discov. 9, 867–882 (2010).
Sampat, B.N. & Lichtenberg, F.R. What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Aff. 30, 332–339 (2011).
Stevens, A.J., Jensen, J.J., Wyller, K., Chatterjee, S. & Rohrbaugh, M.L. The role of public sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364, 535–541 (2011).
Pressman, L. Patent licensing under two policy frameworks: implications for patient access to diagnostic tests and licensing practice in the not for profit sector. BNA Life Sciences Law and Industry Report (23 March 2012).
Kesselheim, A.S. An empirical review of major legislation affecting drug development: past experiences, effects and unintended consequences. Milbank Q. 89, 450–502 (2011).
Moses, H. III, Dorsey, E.R., Matheson, D.H. & Their, S.O. Financial anatomy of biomedical research. J. Am. Med. Assoc. 294, 1333–1342 (2005).
National Institutes of Health. NIH Intramural Research at the Threshold of a New Era. http://sourcebook.od.nih.gov/oir/IRP_transition.pdf (2009).
National Institutes of Health Office of Technology Transfer. Fludara The New Benchmark: A Case Study. http://www.ott.nih.gov/sites/default/files/documents/pdfs/FludaraCS.pdf (2003).
Dorsey, E.R. et al. Financial anatomy of biomedical research 2003–2008. J. Am. Med. Assoc. 303, 137–143 (2010).
Mullin, R. Abbott defends Norvir price hike. Chem. Eng. News 82, 6 (2004).
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., Greyson, D. The cost of drug development: a systematic review. Health Policy. 100, 4–17 (2010).
Milstein, J.B., Batson, A. & Wertheimer, A.I. Vaccines and Drugs: Characteristics of Their Use to Meet Public Health Goals. http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627–1095698140167/MilstienVaccinesDrugsFinal.pdf (2005).
National Institutes of Health. Actual Obligations by Institute and Center, FY 2000 - FY 2012 (2010).